hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 17:33:33 - browse：6729

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

WSS

Why Talkspace is targeting Medicare, a tricky market

Ozempic has benefits for kidney disease as well as diabetes

Creating egg and sperm cells from stem cells raises ethical issues

Pregnant women don't need prenatal multivitamins, study concludes

Florida health officials providing scant details on measles cases

Why Talkspace is targeting Medicare, a tricky market

entertainment

hotspot

explore

ChatGPT in medicine: STAT answers readers' burning questions

CVS Caremark has created a new ploy: the drug ‘rebate credit’

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden's 'march

ChatGPT in medicine: STAT answers readers' burning questions

Baby aspirin cuts fat buildup in liver disease patients, in small study

Supreme Court strikes down use of affirmative action

Why Talkspace is targeting Medicare, a tricky market

How to save PrEP access — and even expand it

Intermittent fasting comes with a heart risk? Not so fast

hotspot

AstraZeneca to buy developer of next

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Creating egg and sperm cells from stem cells raises ethical issues

Longer MASH drug regimen improved liver, Akero study finds

Stop the failed accountable care organization experiment

Baby aspirin cuts fat buildup in liver disease patients, in small study

explore

focus

Wikipedia

entertainment